53910-25-1 Usage
Description
Different sources of media describe the Description of 53910-25-1 differently. You can refer to the following data:
1. Pentostatin, an adenosine deaminase inhibitor, is an orphan drug introduced for the
treatment of hairy cell leukemia. The agent is considered a significant advance over
alpha-interferon, the only other drug available for this indication. The majority of
patients treated with pentostatin have been reported to remain in remission for at least
four years. It is also under investigation for the treatment of other kinds of leukemia
and in transplant rejection.
2. Because of their antitumor activity via inhibition of DNA synthesis, purine nucleoside derivatives resistant to deamination have been developed for the treatment of various leukemias. Pentostatin is a purine nucleoside analog that irreversibly inhibits adenosine deaminase (Ki = 0.9 pM) and thus interrupts DNA synthesis in dividing cells. Pentostatin has been reported to display strong efficacy in the clinical treatment of hairy cell leukemia as well as relapsed chronic lymphocytic leukemia.
Chemical Properties
White Solid
Originator
Warner-Lambert (Parke-Davis) (U.S.A.)
Uses
Different sources of media describe the Uses of 53910-25-1 differently. You can refer to the following data:
1. Pentostatin is a potent antitumour antibiotic isolated from a Streptomyces species. Pentostatin is a potent inhibitor of adenine deaminase and has been used therapeutically as an antitumour agent.
2. Pentostatin is a potent antitumor antibiotic isolated from a Streptomyces species. Pentostatin is a potent inhibitor of adenine deaminase and has been used therapeutically as an antitumor agent.
3. An adenosine deaminase inhibitor used as an anti-cancer therapeutic drug. Shown to be effective in the treatment of hairy cell leukemia as well as having use in the treatment of other types of cancer such as chronic lymphocytic leukemia.
Indications
Pentostatin (Nipent, deoxycoformycin) is a purine isolated
from fermentation cultures of the microbe
Streptomyces antibioticus. Its mechanism of action involves
inhibition of the enzyme adenosine deaminase,
which plays an important role in purine salvage pathways
and DNA synthesis.The resulting accumulation of
deoxyadenosine triphosphate (dATP) is highly toxic to
lymphocytes.
Pentostatin is effective in the therapy of hairy cell
leukemia, producing remissions in 80 to 90% of patients
and complete remissions in more than 50%. The major
toxic effects of the drug include myelosuppression, nausea,
and skin rashes.
Brand name
Nipent (SuperGen).
General Description
The drug is available in 10-mg vials for IV use. The drug isused to treat leukemias such as hairy cell leukemia, chroniclymphocytic leukemia, and lymphoblastic leukemia. Themechanism of action involves inhibition of the enzymeadenosine deaminase yielding increased cellular levels ofdeoxyadenosine and deoxyadenosine triphosphate (dATP).The increased levels of dATP are cytotoxic to lymphocytes.Pentostatin is a fermentation product of Streptomyces antibioticus.Resistance appears to involve decreased cellulartransport or increased expression of catabolic enzymes.Acid instability prevents oral administration, and the drug isonly administered by IV. The drug is distributed in totalbody water but does not enter the CNS. The majority of thedosage is excreted unchanged in the urine. Fatal pulmonary toxicity has occurred when pentostatin and fludarabine areused in combination. Toxicities include myelosuppression,immunosuppression, nausea, vomiting, headache, lethargy,and fatigue.
Biological Activity
Irreversible inhibitor of adenosine deaminase (K i = 2.5 pM). Anticancer agent.
Biochem/physiol Actions
Pentostatin/2′-deoxycoformycin is used to treat patients with Waldenstr?m′s macroglobulinemia.
Clinical Use
Pentostatin is a ring-expanded purine ribonucleoside that inhibits adenosine deaminase and is
used in the treatment of hairy cell leukemia. The elevated levels of deoxyadenosine triphosphate that result
from inhibition of this degradative enzyme inhibit the action of ribonucleotide reductase (the enzyme that
converts ribose diphosphate to deoxyribose diphosphate), thus halting DNA synthesis within the tumor cell.
Safety Profile
Poison by intravenous route. An experimental teratogen. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Drug interactions
Potentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine (increased risk
of agranulocytosis).
Cytotoxics: increased risk of toxicity with high-dose
cyclophosphamide - avoid; increased pulmonary
toxicity with fludarabine (unacceptably high
incidence of fatalities).
Metabolism
Only a small amount is metabolised via the liver.
It is primarily excreted unchanged by the kidneys
(30-90% excreted by kidneys within 24 hours).
Check Digit Verification of cas no
The CAS Registry Mumber 53910-25-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,9,1 and 0 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 53910-25:
(7*5)+(6*3)+(5*9)+(4*1)+(3*0)+(2*2)+(1*5)=111
111 % 10 = 1
So 53910-25-1 is a valid CAS Registry Number.
InChI:InChI=1/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9?/m0/s1
53910-25-1Relevant articles and documents
METHOD FOR THE SYNTHESIS OF PENTOSTATIN
-
Page/Page column 7; 8, (2018/03/28)
The present invention relates to a method for the stereo-selective production of pentostatin comprising an enzymatic transglycosylation reaction between 6,7-dihydroimidazo-[4,5-d]-[1,3]diazepin-8(3H)-one and a 2'-deoxyribonucleoside, followed by an ruthenium-catalyzed asymmetric transfer hydrogenation.
THERAPEUTIC FOR HEPATIC CANCER
-
, (2011/02/18)
A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.
SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES
-
, (2008/06/13)
Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided for total chemical synthesis of pentostatin via a route of heterocyclic ring expansion. For example, a heterocyclic pharmaceutical intermediate for drugs such as pentostatin, e.g., the diazepinone precursor, can be obtained efficiently through a ring expansion of an O-C-N functionality in a hypoxanthine or 2'-deoxyinosine derivative. The methods and compositions can also be used to synthesize and manufacture heterocyclic compounds other than pentostatin, especially pharmaceutically important heterocyclic compounds.
